April 22, 2025
A new position statement from the American Academy of Sleep Medicine (AASM) highlights sleepiness as a key symptom of sleep-wake disorders and a range of psychiatric […]
April 21, 2025
Migraine with aura is the most prominent individual risk factor for unexplained stroke in adults younger than 50 years, particularly in women and in those with […]
April 21, 2025
A French start-up, Robeauté, has raised €27 million ($29 million) to advance the development of its neurosurgical microrobot. This rice-sized device is designed to navigate the […]
April 18, 2025
The US Food and Drug Administration (FDA) has granted marketing authorization to CT-132 (Click Therapeutics), an adjunctive, first-in-class prescription digital therapeutic for the preventive treatment of […]
April 17, 2025
A new systematic review has identified 17 modifiable risk factors shared by at least two of three major age-related brain disorders — stroke, dementia, and late-life […]
April 17, 2025
Two early-stage clinical trials demonstrate the safety and potential effectiveness of stem cell therapies to treat Parkinson’s disease (PD), the second most common neurological disease worldwide. […]
April 16, 2025
Twenty-five years ago, stroke care in the United States was fragmented, and hospitals, for the most part, weren’t adhering to evidence-based guidelines. The majority of stroke […]
April 16, 2025
SAN DIEGO — The investigational drug AXS-12 (reboxetine, Axsome Therapeutics) is safe and effective for the treatment of cataplexy (emotionally induced muscle weakness) and excessive daytime […]
April 15, 2025
SAN DIEGO — Tavapadon, a novel and highly selective partial agonist of dopamine D1 and D5 receptors, significantly improved motor function without increasing impulse control disorders […]